A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Pemetrexed (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 May 2009 Actual end date changed from Nov 2006 to Mar 2009 as reported by ClinicalTrials.gov.
- 31 Oct 2007 Status changedvfrom in progress to completed